Ethnic sensitivity assessment: Polatuzumab vedotin pharmacokinetics in Asian and non‐Asian patients with previously untreated diffuse large B‐cell lymphoma in POLARIX
Abstract This ethnic sensitivity analysis used data from the phase III POLARIX study (NCT03274492) to assess polatuzumab vedotin pharmacokinetics (PKs) in Asian versus non‐Asian patients with previously untreated diffuse large B‐cell lymphoma and examined the appropriateness of extrapolating global...
Saved in:
Main Authors: | Michael Z. Liao (Author), Rong Deng (Author), Leonid Gibiansky (Author), Tong Lu (Author), Priya Agarwal (Author), Randall Dere (Author), Calvin Lee (Author), Jamie Hirata (Author), Charles Herbaux (Author), Gilles Salles (Author), Chunze Li (Author), Dale Miles (Author) |
---|---|
Format: | Book |
Published: |
Wiley,
2023-12-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Population pharmacokinetics and exposure-response analyses of polatuzumab vedotin in patients with previously untreated DLBCL from the POLARIX study
by: Rong Deng, et al.
Published: (2024) -
Integrated Two‐Analyte Population Pharmacokinetic Model of Polatuzumab Vedotin in Patients With Non‐Hodgkin Lymphoma
by: Dan Lu, et al.
Published: (2020) -
Primary Thyroid Lymphoma: A Rare Diagnosis Treated With Polatuzumab Vedotin
by: Rupam Sharma MD, et al.
Published: (2024) -
A real-world pharmacovigilance study of polatuzumab vedotin based on the FDA adverse event reporting system (FAERS)
by: Dan Liu, et al.
Published: (2024) -
Advances in Polatuzumab Vedotin-PIIQ Therapy: A Review of Treatment Efficacy in Diffuse Large B Cell Lymphoma and High-Grade B Cell Lymphoma
by: Abdur Raqib M, et al.
Published: (2023)